ACE and cancer: While Ang II has been used in cancer to enable better accessibility of chemotherapeutic drugs to the tumour (Noguchi et al, 1988), Ang II blockers and ACE inhibitors have nevertheless been shown to reduce tumour size, angiogenesis and metastasis (Fujita et al, 2002; Uemura et al, 2005), although the suggestion that long-term use of angiotensin converting enzyme (ACE) inhibitors in patients may limit the development of cancer (Lever et al, 1998) has been questioned (Li et al, 2003; Ronquist et al, 2004).